ABOS

Acumen Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website acumenpharm.com
Employees(FY) 39
ISIN US00509G2093

Performance

-10.63%

-22.59%

-28.29%

-20.6%

-51.82%

YTD

-39.94%

Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Advanced Technical Analysis

Technical Analysis of ABOS 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance, and the Technical Score of 33 reinforces the bearish outlook. This combination implies that while there may be some oscillatory movements, the prevailing tre...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ABOS

Stock Rank

Recent News & Updates

2024-11-26 03:00
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference(Globenewswire)
2024-11-12 13:06
Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...(Yahoo Finance)
2024-11-12 09:54
Q3 2024 Acumen Pharmaceuticals Inc Earnings Call(Yahoo Finance)
2024-11-11 18:00
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-11-11 03:00
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference(Globenewswire)
2024-11-06 03:00
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference(Globenewswire)
2024-11-05 19:00
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality(Globenewswire)
2024-11-05 03:00
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024(Globenewswire)
2024-10-30 20:05
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference(Globenewswire)
2024-10-22 20:00
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference(Globenewswire)
2024-09-30 04:00
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference(Globenewswire)
2024-09-26 19:46
Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug(Pharmaceutical-business-review)
2024-09-25 20:00
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease(Globenewswire)
2024-09-25 04:00
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024(Globenewswire)
2024-09-03 04:00
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference(Globenewswire)
2024-08-13 11:26
Q2 2024 Acumen Pharmaceuticals Inc Earnings Call(Yahoo Finance)
2024-08-12 19:00
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-08-06 04:00
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024(Globenewswire)
2024-07-28 19:00
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease(Globenewswire)
2024-07-27 19:30
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC ) 2024(Globenewswire)
2024-07-10 20:00
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC ) 2024(Globenewswire)
2024-06-20 23:13
Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds?(Insidermonkey)
2024-06-20 22:53
7 Best Halal Stocks To Buy Now (Debt Free)(Insidermonkey)
2024-05-14 15:00
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...(Yahoo Finance)
2024-05-14 14:06
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call(Yahoo Finance)
2024-05-13 23:53
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024(Investorplace)
2024-05-13 19:00
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-05-13 04:00
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference(Globenewswire)
2024-05-12 22:15
Arthur J. Gallagher Acquires Acumen Advisors(Yahoo Finance)
2024-05-08 05:47
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.